WA
NVS icon

Wambolt & Associates’s Novartis NVS Stock Holding History

Wambolt & Associates’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$3.16M Sell
25,647
-1,374
-5% -$155K 1.06% 28
2025
Q1 		$2.96M Buy
27,021
+443
+2% +$47.2K 1.01% 32
2024
Q4 		$2.59M Sell
26,578
-5,011
-16% -$534K 0.83% 38
2024
Q3 		$3.62M Buy
31,589
+1,399
+5% +$159K 0.99% 30
2024
Q2 		$3.22M Buy
30,190
+1,965
+7% +$197K 0.93% 32
2024
Q1 		$2.71M Buy
28,225
+3,425
+14% +$351K 0.81% 38
2023
Q4 		$2.5M Buy
24,800
+3,480
+16% +$336K 0.82% 31
2023
Q3 		$2.16M Buy
21,320
+1,899
+10% +$193K 0.79% 33
2023
Q2 		$1.96M Buy
19,421
+742
+4% +$74.2K 0.7% 36
2023
Q1 		$1.73M Buy
18,679
+729
+4% +$63.7K 0.61% 47
2022
Q4 		$1.63M Buy
17,950
+552
+3% +$46.5K 0.63% 48
2022
Q3 		$1.32M Buy
17,398
+179
+1% +$14.8K 0.56% 61
2022
Q2 		$1.46M Buy
17,219
+904
+6% +$79.3K 0.59% 58
2022
Q1 		$1.43M Buy
16,315
+738
+5% +$63.9K 0.52% 70
2021
Q4 		$1.36M Buy
15,577
+1,690
+12% +$140K 0.49% 70
2021
Q3 		$1.14M Buy
13,887
+936
+7% +$84.2K 0.46% 82
2021
Q2 		$1.19M Sell
12,951
-370
-3% -$32.9K 0.5% 69
2021
Q1 		$1.15M Buy
13,321
+819
+7% +$73.5K 0.6% 63
2020
Q4 		$1.18M Buy
12,502
+560
+5% +$48.9K 0.71% 43
2020
Q3 		$1.04M Buy
11,942
+517
+5% +$44.8K 0.78% 39
2020
Q2 		$998K Buy
11,425
+787
+7% +$67.9K 0.78% 35
2020
Q1 		$877K Buy
10,638
+496
+5% +$44.3K 0.91% 32
2019
Q4 		$960K Buy
10,142
+811
+9% +$72.8K 0.73% 41
2019
Q3 		$811K Sell
9,331
-167
-2% -$15K 0.67% 48
2019
Q2 		$867K Buy
9,498
+284
+3% +$24K 0.73% 40
2019
Q1 		$689K Buy
9,214
+680
+8% +$54.6K 0.63% 47
2018
Q4 		$656K Buy
+8,534
New +$664K 0.72% 37

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wambolt & Associates's NVS Position: Q2 2025 in Review

Wambolt & Associates reduced its Novartis (NVS) stake by 5.1% in Q2 2025, selling an estimated $155K and leaving 25,647 shares worth $3.16M. The position accounts for 1.06% of the portfolio, ranked #28.

Wambolt & Associates first reported a position in NVS in Q4 2018 and has held it in 27 quarters since. The position peaked at $3.62M in Q3 2024. 1,384 funds tracked by Wall St. Rank hold NVS as of Q2 2025.

  • Wambolt & Associates held 25,647 shares of Novartis worth $3.16M as of Q2 2025.
  • Wambolt & Associates sold 1,374 Novartis shares in Q2 2025, an estimated $155K.
  • Novartis made up 1.06% of Wambolt & Associates's portfolio in Q2 2025, its #28 holding.
  • Wambolt & Associates first reported a position in Novartis in Q4 2018 and has held it in 27 quarters since.
  • Wambolt & Associates's Novartis position peaked at $3.62M in Q3 2024.
  • 1,384 funds tracked by Wall St. Rank held Novartis as of Q2 2025.

Based on Wambolt & Associates's 13F filing for Q2 2025, filed 13 Aug 2025.